Actively Recruiting

All Genders
NCT06536179

New Preclinical and Clinical Approaches to Mesothelioma

Led by Marco Emilio Bianchi · Updated on 2024-08-02

70

Participants Needed

2

Research Sites

130 weeks

Total Duration

On this page

Sponsors

M

Marco Emilio Bianchi

Lead Sponsor

I

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.

CONDITIONS

Official Title

New Preclinical and Clinical Approaches to Mesothelioma

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with clinical suspicion or histologically confirmed pleural mesothelioma
  • Candidates for surgical intervention
  • Age 18 years or older
  • Both male and female patients, including reproductive age and breastfeeding women
  • Ability to understand the study and provide autonomous informed consent
  • Control group patients with other histologically confirmed diseases (neoplastic, inflammatory, or infectious) without pleural mesothelioma
  • Control group candidates for surgical intervention
  • Control group patients aged 18 years or older
  • Control group includes both male and female patients, including reproductive age and breastfeeding women
  • Control group ability to understand the study and provide autonomous informed consent
Not Eligible

You will not qualify if you...

  • Lack of biopsy material
  • Pregnancy
  • Unwillingness to sign the Informed Consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Istituto Nazionale Tumori IRCCS Fondazione G.Pascale

Naples, Campania, Italy, 80131

Actively Recruiting

2

IRCCS San Raffaele

Milan, Lombardy, Italy, 20132

Actively Recruiting

Loading map...

Research Team

M

Massimo Crippa, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here